BioCentury
ARTICLE | Company News

Amicus to build U.S. biologics facility

February 2, 2018 8:21 PM UTC

Amicus Therapeutics Inc. (NASDAQ:FOLD) plans to spend up to $200 million to build a new biologics facility in the U.S. for its Pompe's disease program, CEO and Chairman John Crowley told BioCentury. The company said various locations outside the U.S. had been under consideration...

BCIQ Company Profiles

Amicus Therapeutics Inc.

BCIQ Target Profiles

Acid alpha glucosidase (GAA)